NCT04960462 is a clinical trial of nerve root sleeve reinforcement in Tarlov Cysts, sponsored by Peking University Third Hospital.

Who is sponsoring NCT04960462?

NCT04960462 is sponsored by Peking University Third Hospital.

What drugs are being tested in NCT04960462?

Interventions in NCT04960462: nerve root sleeve reinforcement.

What condition does NCT04960462 study?

NCT04960462 studies Tarlov Cysts.

Is NCT04960462 still recruiting?

NCT04960462 is currently completed. Last updated 13 July 2021.

Last reviewed 2021-07-13 · How we verify

NCT04960462

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Case Report of Nerve Root Sleeve Reinforcement and Reconstruction and Sacral Canal Plasty for the Treatment of Sacral Canal

Completed Last updated 13 July 2021

What this trial tests

trial testing nerve root sleeve reinforcement in Tarlov Cysts in 24 participants. Completed in 30 April 2018.

Timeline

1 August 2017

Primary endpoint
30 January 2018

30 April 2018

Quick facts

Lead sponsor	Peking University Third Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	24
Start date	1 August 2017
Primary completion	30 January 2018
Estimated completion	30 April 2018
Sites	1 location across China

Drugs / interventions tested

nerve root sleeve reinforcement

Conditions studied

Tarlov Cysts — all drugs for Tarlov Cysts →

Sponsor

Peking University Third Hospital

Who can join

Eligibility, any sex, with Tarlov Cysts. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A retrospective study of the changes in the VAS scores and imaging examinations after the reconstruction and reinforcement of nerve root sleeves and caudal angioplasty for the treatment of sacral cysts from August 2017 to January 2018 was used to evaluate the efficacy of the surgical prescription.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Peking University Third Hospital trials

Trials by the same sponsor.

NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
NCT07470255 — Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters · not yet recruiting
NCT07453381 — Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective · not yet recruiting
NCT07452354 — AI-Based Diabetic Foot Recurrence Cohort · not yet recruiting
NCT07423819 — Sports Rehabilitation Therapy for Knee Joint Sports Injuries: A Case Study of Anterior Cruciate Ligament Injury and Pate · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04960462 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University Third Hospital
Last refreshed: 13 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04960462.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing